Arms racing between human beings and pathogens: NDM-1 and superbugs

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 26, Issue 11, 2010, Pages 1461-1472

  Sun, Mingwei ^a,b   Zheng, Beiwen ^a,c   Gao, George F ^a,d   Zhu, Baoli ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Arms racing; NDM 1; Resistance gene; Superbugs

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE NDM 1; BETA-LACTAMASE NDM-1;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; DRUG EFFECT; GENETICS; HORIZONTAL GENE TRANSFER; MUTATION; PLASMID;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; GENE TRANSFER, HORIZONTAL; MUTATION; PLASMIDS;

BACTERIA (MICROORGANISMS);

EID: 79851476196     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis, 2010, 10(9): 597-602.
2. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother, 2009, 53(12): 5046-5054.
3. Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Infect Control, 2006, 34(5 Suppl 1): S20-28; discussion S64-73.
4. Agency HP. Multi-resistant hospital bacteria linked to India and Pakistan. Health Protection Report, 2009, 3(26): 3-4.
5. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc Lond B Biol Sci, 1922, 93: 306-317.
6. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol, 1929, 10: 226-236.
7. Pasteur L, Joubert JF. Charbon et septicémie. C R Soc Biol (Paris), 1877, 85: 101-115.
8. Babes V, Cornil J. Med Prat (Paris), 1885, 7: 321.
9. Garre C. Ueber Antagonisten unter den bacterien. Correspondenz-Blatt für Schweizer Aerzte, 1887, 17: 385-392.
10. Emmerich. R, Low O. Bakteriolytische Enzyme als Ursache der erworbenen Immunitat und die Heilung von Infektionskrankheiten durch dieselben. Z Hyg InfektKr, 1899, 31: 1.
11. Foster W, Raoult A. Early descriptions of antibiosis. J R Coll Gen Pract, 1974, 24(149): 889-894.
12. Doetsch RN. Studies on biogenesis by Sir William Roberts. Med Hist, 1963, 7: 232-240.
13. Majno G, Joris I. Billroth and Penicillium. Rev Infect Dis, 1979, 1(5): 880-884.
14. Thiele-Bruhn S. Pharmaceutical antibiotic compounds in soils - a review. J Plant Nutrition Soil Science-Zeitschrift Fur Pflanzenernahrung Und Bodenkunde, 2003, 166(2): 145-167.
15. Cabello FC. Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol, 2006, 8(7): 1137-1144.
16. Sarmah AK, Meyer MT, Boxall ABA. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. Chemosphere, 2006, 65(5): 725-759.
17. Allen HK, Donato J, Wang HH, et al. Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol, 2010, 8(4): 251-259.
18. Nies DH. Efflux-mediated heavy metal resistance in prokaryotes. FEMS Microbiol Rev, 2003, 27(2/3): 313-339.
19. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother, 2005, 56(1): 20-51.
20. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother, 1992, 36(4): 695-703.
21. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother, 2000, 44(7): 1771-1777.
22. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science, 1994, 264(5157): 375-382.
23. Thomas CM, Nielsen KM. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nature Rev Microbiol, 2005, 3(9): 711-721.
24. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol, 2010, 8(4): 260-271.
25. Lubelski J, Konings WN, Driessen AJ. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev, 2007, 71(3): 463-476.
26. Macinga DR, Rather PN. The chromosomal 2'-N- acetyltransferase of Providencia stuartii: physiological functions and genetic regulation. Front Biosci, 1999, 4: D132-140.
27. Franklin K, Clarke AJ. Overexpression and characterization of the chromosomal aminoglycoside 2'-N-acetyltransferase of Providencia stuartii. Antimicrob Agents Chemother, 2001, 45(8): 2238-2244.
28. Martinez JL. Antibiotics and antibiotic resistance genes in natural environments. Science, 2008, 321(5887): 365-367.
29. Goh EB, Yim G, Tsui W, et al. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc Natl Acad Sci USA, 2002, 99(26): 17025-17030.
30. Fajardo A, Martinez JL. Antibiotics as signals that trigger specific bacterial responses. Curr Opin Microbiol, 2008, 11(2): 161-167.
31. Penicillin's Finder Assay's It's Future: Sir Alexander Flemming Says Improved Dosing. Method Is needed to Extend Use. N. Y. Times, 1945: 13.
32. Cirz RT, Chin JK, Andes DR, et al. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol, 2005, 3(6): e176.
33. Linares JF, Gustafsson I, Baquero F, et al. Antibiotics as intermicrobial signaling agents instead of weapons. Proc Natl Acad Sci USA, 2006, 103(51): 19484-19489.
34. Taubes G. The bacteria fight back. Science, 2008, 321(5887): 356-361.
35. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med, 2007, 13(12): 1510-1514.
36. Grundmann H, Aires-de-Sousa M, Boyce J, et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet, 2006, 368(9538): 874-885.
37. Lee BY, Bailey RR, Smith KJ, et al. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect Control Hosp Epidemiol, 2010, 31(6): 598-606.
38. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug- resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol, 2006, 55(Pt 12): 1619-1629.
39. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis, 2008, 46(7): 1121-1122; author reply 1122.
40. McGowan JE, Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control, 2006, 34(5 Suppl 1): S29-37; discussion S64-73.
41. Kuo LC, Teng LJ, Yu CJ, et al. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol, 2004, 42(4): 1759-1763.
42. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. Morb Mortal Wkly Rep, 2006, 55(11): 301-305.
43. Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. Morb Mortal Wkly Rep, 2006, 55(43): 1176.
44. Su WJ. Extensively drug-resistant tuberculosis (XDR-TB) raises challenges in TB control in Taiwan. J Formos Med Assoc, 2008, 107(11): 827-829.
45. Malbruny B, Nagai K, Coquemont M, et al. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother, 2002, 49(6): 935-939.
46. Pihlajamaki M, Kataja J, Seppala H, et al. Ribosomal mutations in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother, 2002, 46(3): 654-658.
47. CDC. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR, 1997, 46: 1-24.
48. Hogberg L, Henriques Normark B, Ringberg H, et al. The impact of active intervention on the spread of penicillin- resistant Streptococcus pneumoniae in Swedish day-care centres. Scand J Infect Dis, 2004, 36(9): 629-635.
49. Kim NJ, Park SJ, Choi SH, et al. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and in vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae. Microb Drug Resist, 2005, 11(3): 260-265.
50. Tamayo J, Perez-Trallero E, Gomez-Garces JL, et al. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother, 2005, 56(4): 780-782.
51. Sener B, Koseoglu O, Gur D, et al. Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey. J Chemother, 2005, 17(1): 31-35.
52. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother, 2002, 46(9): 2727-2734.
53. Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis, 2006, 42(6): 788-797.
54. Farrell DJ, Morrissey I, Bakker S, et al. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother, 2004, 48(8): 3169-3171.
55. Dixson S, Brumfitt W, Hamilton-Miller JM. In vitro activity of six antibiotics against multiresistant staphylococci and other gram-positive cocci. Eur J Clin Microbiol, 1985, 4(1): 19-23.
56. Harwood VJ, Brownell M, Perusek W, et al. Vancomycin- resistant Enterococcus spp. isolated from wastewater and chicken feces in the United States. Appl Environ Microbiol, 2001, 67(10): 4930-4933.
57. Cox LA Jr, Popken DA. Quantifying human health risks from virginiamycin used in chickens. Risk Anal, 2004, 24(1): 271-288.
58. Agerso Y, Lester CH, Porsbo LJ, et al. Vancomycin- resistant Enterococcus faecalis isolates from a Danish patient and two healthy human volunteers are possibly related to isolates from imported turkey meat. J Antimicrob Chemother, 2008, 62(4): 844-845.
59. Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol, 2008, 16(8): 361-369.
60. Lipin MY, Stepanshina VN, Shemyakin IG, et al. Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin Microbiol Infect, 2007, 13(6): 620-626.
61. Rozen DE, McGee L, Levin BR, et al. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother, 2007, 51(2): 412-416.
62. Bjorkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA, 1998, 95(7): 3949-3953.
63. Nilsson AI, Zorzet A, Kanth A, et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci USA, 2006, 103(18): 6976-6981.
64. Schrag SJ, Perrot V. Reducing antibiotic resistance. Nature, 1996, 381(6578): 120-121.
65. Reynolds MG. Compensatory evolution in rifampin- resistant Escherichia coli. Genetics, 2000, 156(4): 1471-1481.
66. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog, 2009, 5(8): e1000541.
67. Fermer C, Swedberg G. Adaptation to sulfonamide resistance in Neisseria meningitidis may have required compensatory changes to retain enzyme function: kinetic analysis of dihydropteroate synthases from N. meningitidis expressed in a knockout mutant of Escherichia coli. J Bacteriol, 1997, 179(3): 831-837.
68. Luo N, Pereira S, Sahin O, et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA, 2005, 102(3): 541-546.
69. Bjorkholm B, Sjolund M, Falk PG, et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci USA, 2001, 98(25): 14607-14612.
70. Kanai K, Shibayama K, Suzuki S, et al. Growth competition of macrolide-resistant and -susceptible Helicobacter pylori strains. Microbiol Immunol, 2004, 48(12): 977-980.
71. Kugelberg E, Lofmark S, Wretlind B, et al. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother, 2005, 55(1): 22-30.
72. Poirel L, Lebessi E, Castro M, et al. Nosocomial outbreak of extended-spectrum beta-lactamase SHV-5-producing isolates of Pseudomonas aeruginosa in Athens, Greece. Antimicrob Agents Chemother, 2004, 48(6): 2277-2279.
73. Bacher JM, Schimmel P. An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response. Proc Natl Acad Sci USA, 2007, 104(6): 1907-1912.
74. Gupta A, Bhakta S, Kundu S, et al. Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening. J Antimicrob Chemother, 2009, 64(4): 774-781.
75. Fuller R. Probiotics in man and animals. J Appl Bacteriol, 1989, 66(5): 365-378.
76. Fuller R. Probiotics in human medicine. Gut, 1991, 32(4): 439-442.
77. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr, 2001, 73(2 Suppl): 465S-470S.